S&P 500   3,322.57 (+0.17%)
DOW   29,319.84 (+0.08%)
QQQ   222.43 (+0.07%)
AAPL   315.89 (+0.21%)
MSFT   165.52 (-0.39%)
GOOGL   1,464.15 (+0.96%)
AMZN   1,864.27 (-0.73%)
CGC   24.57 (+1.11%)
BABA   226.09 (+0.96%)
MU   57.13 (-0.95%)
GE   11.81 (-0.34%)
TSLA   509.77 (-0.72%)
AMD   50.48 (+1.41%)
T   38.34 (+0.79%)
ACB   2.10 (-2.33%)
F   9.17 (-0.11%)
NFLX   338.31 (-0.09%)
BAC   34.65 (-0.20%)
GILD   62.98 (-0.35%)
DIS   144.97 (-0.10%)
S&P 500   3,322.57 (+0.17%)
DOW   29,319.84 (+0.08%)
QQQ   222.43 (+0.07%)
AAPL   315.89 (+0.21%)
MSFT   165.52 (-0.39%)
GOOGL   1,464.15 (+0.96%)
AMZN   1,864.27 (-0.73%)
CGC   24.57 (+1.11%)
BABA   226.09 (+0.96%)
MU   57.13 (-0.95%)
GE   11.81 (-0.34%)
TSLA   509.77 (-0.72%)
AMD   50.48 (+1.41%)
T   38.34 (+0.79%)
ACB   2.10 (-2.33%)
F   9.17 (-0.11%)
NFLX   338.31 (-0.09%)
BAC   34.65 (-0.20%)
GILD   62.98 (-0.35%)
DIS   144.97 (-0.10%)
S&P 500   3,322.57 (+0.17%)
DOW   29,319.84 (+0.08%)
QQQ   222.43 (+0.07%)
AAPL   315.89 (+0.21%)
MSFT   165.52 (-0.39%)
GOOGL   1,464.15 (+0.96%)
AMZN   1,864.27 (-0.73%)
CGC   24.57 (+1.11%)
BABA   226.09 (+0.96%)
MU   57.13 (-0.95%)
GE   11.81 (-0.34%)
TSLA   509.77 (-0.72%)
AMD   50.48 (+1.41%)
T   38.34 (+0.79%)
ACB   2.10 (-2.33%)
F   9.17 (-0.11%)
NFLX   338.31 (-0.09%)
BAC   34.65 (-0.20%)
GILD   62.98 (-0.35%)
DIS   144.97 (-0.10%)
S&P 500   3,322.57 (+0.17%)
DOW   29,319.84 (+0.08%)
QQQ   222.43 (+0.07%)
AAPL   315.89 (+0.21%)
MSFT   165.52 (-0.39%)
GOOGL   1,464.15 (+0.96%)
AMZN   1,864.27 (-0.73%)
CGC   24.57 (+1.11%)
BABA   226.09 (+0.96%)
MU   57.13 (-0.95%)
GE   11.81 (-0.34%)
TSLA   509.77 (-0.72%)
AMD   50.48 (+1.41%)
T   38.34 (+0.79%)
ACB   2.10 (-2.33%)
F   9.17 (-0.11%)
NFLX   338.31 (-0.09%)
BAC   34.65 (-0.20%)
GILD   62.98 (-0.35%)
DIS   144.97 (-0.10%)
Log in

NASDAQ:ALNY - Alnylam Pharmaceuticals Stock Price, Forecast & News

$117.66
-1.68 (-1.41 %)
(As of 01/17/2020 12:02 PM ET)
Today's Range
$116.17
Now: $117.66
$119.44
50-Day Range
$114.65
MA: $118.10
$124.28
52-Week Range
$65.81
Now: $117.66
$125.72
Volume9,339 shs
Average Volume619,791 shs
Market Capitalization$13.12 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.44
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. It provides ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ALNY
CUSIP02043Q10
Phone617-551-8200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$74.91 million
Book Value$12.87 per share

Profitability

Net Income$-761,490,000.00
Net Margins-485.73%

Miscellaneous

Employees1,065
Market Cap$13.12 billion
Next Earnings Date2/6/2020 (Estimated)
OptionableOptionable

Receive ALNY News and Ratings via Email

Sign-up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter.


Revealed... The Top 3 Stocks for 2020 (Ad)


Investors looking for the best way to potentially double their money in 2020 -- regardless of whether the overall markets are up or down -- should look no further than these 3 unique stocks.

This Special Report reveals the names of these stocks and provides everything you need to invest right away.

Alnylam Pharmaceuticals (NASDAQ:ALNY) Frequently Asked Questions

What is Alnylam Pharmaceuticals' stock symbol?

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

How were Alnylam Pharmaceuticals' earnings last quarter?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) posted its earnings results on Thursday, October, 31st. The biopharmaceutical company reported ($1.92) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($2.17) by $0.25. The biopharmaceutical company had revenue of $70.06 million for the quarter, compared to analyst estimates of $57.14 million. Alnylam Pharmaceuticals had a negative net margin of 485.73% and a negative return on equity of 52.88%. The business's quarterly revenue was up 3284.5% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.56) EPS. View Alnylam Pharmaceuticals' Earnings History.

When is Alnylam Pharmaceuticals' next earnings date?

Alnylam Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for Alnylam Pharmaceuticals.

What price target have analysts set for ALNY?

17 analysts have issued 1-year price targets for Alnylam Pharmaceuticals' shares. Their forecasts range from $62.00 to $190.00. On average, they anticipate Alnylam Pharmaceuticals' share price to reach $121.59 in the next twelve months. This suggests a possible upside of 3.1% from the stock's current price. View Analyst Price Targets for Alnylam Pharmaceuticals.

What is the consensus analysts' recommendation for Alnylam Pharmaceuticals?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 1 sell rating, 4 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alnylam Pharmaceuticals.

What are Wall Street analysts saying about Alnylam Pharmaceuticals stock?

Here are some recent quotes from research analysts about Alnylam Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Alnylam incurred narrower-than-expected loss and beat revenue estimates in the third quarter of 2019. Onpattro continued to gain traction. The FDA set an action date of Feb 20, 2020. It showed strong commitment toward future pipeline growth through its landmark ocular and CNS disease alliance with Regeneron. The company also aims to expand the label of Onpattro for patients with cardiomyopathy and a potential label expansion should boost sales.The company’s efforts to develop its pipeline (inclisiran and lumasiran) are impressive. The company also expects to submit an NDA for inclisiran in 2019. Although we are pleased with Alnylam’s broad and promising pipeline, heavy dependence on Onpattro for growth is a concern. Moreover, the company heavily relies on its partnerships for supporting operations.Shares have outperformed the industry." (11/19/2019)
  • 2. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating and $135 price target. Our small/mid-cap analyst Ellie Merle today launched coverage of Ionis (IONS, N). Ionis developed Onpattro competitor Tegsedi, which is now licensed to and commercialized by Akcea (AKCA, NC). We agree that Onpattro has taken meaningful share and that near-term competition from Tegsedi will likely be limited. Here we note relevant key takes from her launch and our perspective on the TTR market. We think that the overall TTR market opportunity is large, but that increasing diagnosis and treatment rates will take time." (4/9/2019)

Has Alnylam Pharmaceuticals been receiving favorable news coverage?

News coverage about ALNY stock has trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Alnylam Pharmaceuticals earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Alnylam Pharmaceuticals.

Are investors shorting Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals saw a drop in short interest in the month of December. As of December 31st, there was short interest totalling 4,420,000 shares, a drop of 10.5% from the December 15th total of 4,940,000 shares. Based on an average daily trading volume, of 694,700 shares, the days-to-cover ratio is currently 6.4 days. Approximately 4.0% of the company's stock are short sold. View Alnylam Pharmaceuticals' Current Options Chain.

Who are some of Alnylam Pharmaceuticals' key competitors?

What other stocks do shareholders of Alnylam Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), NVIDIA (NVDA), NXP Semiconductors (NXPI), Gilead Sciences (GILD), Mylan (MYL), Netflix (NFLX), Opko Health (OPK) and Micron Technology (MU).

Who are Alnylam Pharmaceuticals' key executives?

Alnylam Pharmaceuticals' management team includes the folowing people:
  • Dr. John M. Maraganore, CEO & Exec. Director (Age 56)
  • Mr. Barry E. Greene, Pres (Age 56)
  • Mr. Manmeet Singh Soni, Sr. VP, CFO & Principal Accounting Officer (Age 41)
  • Dr. Yvonne Greenstreet MBChB, MBA, Exec. VP & COO (Age 56)
  • Dr. Akshay K. Vaishnaw, Pres of R&D (Age 56)

Who are Alnylam Pharmaceuticals' major shareholders?

Alnylam Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Peregrine Capital Management LLC (0.14%), DNB Asset Management AS (0.01%), IFM Investors Pty Ltd (0.01%), Polianta Ltd (0.01%), Zeke Capital Advisors LLC (0.00%) and Gateway Investment Advisers LLC (0.00%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, Barry E Greene, John Maraganore, Laurie Keating, Marsha Fanucci, Paul Schimmel, Philip A Sharp, Phillip A Sharp and Yvonne Greenstreet. View Institutional Ownership Trends for Alnylam Pharmaceuticals.

Which institutional investors are selling Alnylam Pharmaceuticals stock?

ALNY stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Zeke Capital Advisors LLC, IFM Investors Pty Ltd and Gateway Investment Advisers LLC. Company insiders that have sold Alnylam Pharmaceuticals company stock in the last year include Barry E Greene, John Maraganore, Marsha Fanucci, Philip A Sharp, Phillip A Sharp and Yvonne Greenstreet. View Insider Buying and Selling for Alnylam Pharmaceuticals.

Which institutional investors are buying Alnylam Pharmaceuticals stock?

ALNY stock was acquired by a variety of institutional investors in the last quarter, including Polianta Ltd, Tocqueville Asset Management L.P., IBM Retirement Fund and DNB Asset Management AS. View Insider Buying and Selling for Alnylam Pharmaceuticals.

How do I buy shares of Alnylam Pharmaceuticals?

Shares of ALNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Alnylam Pharmaceuticals' stock price today?

One share of ALNY stock can currently be purchased for approximately $117.93.

How big of a company is Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals has a market capitalization of $13.15 billion and generates $74.91 million in revenue each year. The biopharmaceutical company earns $-761,490,000.00 in net income (profit) each year or ($7.57) on an earnings per share basis. Alnylam Pharmaceuticals employs 1,065 workers across the globe.View Additional Information About Alnylam Pharmaceuticals.

What is Alnylam Pharmaceuticals' official website?

The official website for Alnylam Pharmaceuticals is http://www.alnylam.com/.

How can I contact Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals' mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-551-8200 or via email at [email protected]


MarketBeat Community Rating for Alnylam Pharmaceuticals (NASDAQ ALNY)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  937 (Vote Outperform)
Underperform Votes:  461 (Vote Underperform)
Total Votes:  1,398
MarketBeat's community ratings are surveys of what our community members think about Alnylam Pharmaceuticals and other stocks. Vote "Outperform" if you believe ALNY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALNY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/17/2020 by MarketBeat.com Staff

Featured Article: Balance Sheet

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel